- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03781375
Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis
A Phase III Double Blind Randomized Study Comparing Etanercept (Enbrel) Combined With Methotrexate vs Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Patients must have had a diagnosis of JRA by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular
- Disease course must have been polyarticular with at least 5 active joints
- Duration of disease was not limited, but must have been long enough for the patient to have been given a 3-month trial of non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate at a dose between 0.3 and 1.0 mg/kg/week, orally (PO) or subcutaneously (SC)
- Receiving methotrexate at a dose between 0.3 mg/kg/wk and 1 mg/kg/wk at time of randomization. The dose of methotrexate must have been stable for one month prior to entry
- Patients may have failed prednisone, or been on a dosage of prednisone not to have exceeded 10 mg/day or 0.20 mg/kg/day (whichever was less)
- At the time of qualification (screening) for study and prior to wash-out of all disease modifying anti-rheumatic drugs (DMARDs), the patient must have had active disease, defined as ≥ 5 swollen joints accompanied by pain, and/or tenderness and/or warmth, and ≥ 3 joints with limitation of motion (LOM). (The joints with LOM may have been the same as those with swelling)
- Had good venous access and stable hematocrit ≥ 24 mL/dL
- Patients must have been pre-pubescent, or if post-pubertal at anytime during the study, and of child-bearing potential, must have been practicing adequate contraception
- Parent or legal guardian was able and willing to give informed consent
- Parent or legal guardian must have been willing to actively supervise storage and administration of study drug and ensure that the date and time of each dose was accurately recorded in the subject's diary
Exclusion Criteria:
- Was unable to meet the concurrent medication restrictions as described in the protocol
- Pregnant or nursing female
Patients were excluded if they demonstrated clinically significant deviations from normal (as defined below) in any of the following laboratory parameters:
- thrombocytopenia; platelet count < 100,000/cmm
- leukopenia; total white cell count < 4000 cells/cmm
- neutropenia; neutrophils < 1000 cells/cmm
- hepatic transaminase levels > two times the upper limit of normal (ULN)
- serum bilirubin > two times the ULN
- estimated creatinine clearance of < 90 mL/min/1.73 M² body surface area (BSA)
- known human immunodeficiency virus (HIV), hepatitis B surface antigen positivity not related to vaccination, or hepatitis C antibody positivity
- Had received etanercept, antibody to tumor necrosis factor (TNF) (i.e. infliximab or D2E7), antibody to cluster of differentiation (CD)4 (anti-CD4), diphtheria interleukin (IL)-2 fusion protein (DAB-IL-2) or leflunomide
- Had received DMARDs including D-penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin, azathioprine; intravenous immunoglobulin (IV Ig); or broadly immunosuppressant chemotherapeutic agents (e.g. cyclophosphamide, FK506, mycophenolate mofetil [CellCept]), for at least 28 days prior to enrollment and dosing of study drug. All DMARDs, other than methotrexate, must have been washed-out for a minimum of 28 days
- Had received intraarticular glucocorticoid injection within 28 days prior to enrollment on study
- Had previously received live virus vaccine within 3 months prior to study entry
- Had participated in a study of an investigational drug or biologic requiring informed-consent within three months prior to study entry
- Any concurrent medical condition which would have, in the investigator's opinion, compromised the patient's ability to tolerate the study drug or would have made the patient unable to cooperate with the protocol
- History of/or current psychiatric illness that would have interfered with ability to comply with protocol requirements or give informed consent
- Chronic or recurrent infections, or currently active infection at screening
- History of alcohol or drug abuse that would have interfered with ability to comply with protocol requirements
- Inability to have complied with the study requirements
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: Methotrexate + Placebo
Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months.
After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
|
Indgives ved subkutan injektion to gange om ugen
Andre navne:
Administered by subcutaneous injection twice a week
Administered orally or subcutaneously once a week at the same dose as prior to study entry
|
Eksperimentel: Methotrexate + Etanercept
Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months.
After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
|
Indgives ved subkutan injektion to gange om ugen
Andre navne:
Administered orally or subcutaneously once a week at the same dose as prior to study entry
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With a JRA Response at Month 6
Tidsramme: Baseline and month 6
|
Response was defined using the JRA definition of improvement (JRA DOI) as a ≥ 30% improvement from baseline in at least three of the six JRA Core Set Criteria and ≥ 30% worsening in not more than one of the six assessments. The JRA Core Set Criteria consist of:
|
Baseline and month 6
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With a 50% Improvement in JRA DOI at Month 6
Tidsramme: Baseline and month 6
|
Response was defined using the JRA definition of improvement (JRA DOI) as a ≥ 50% improvement from baseline in at least three of the six JRA Core Set Criteria and ≥ 30% worsening in not more than one of the six assessments. The JRA Core Set Criteria consist of:
|
Baseline and month 6
|
Percentage of Participants With a 70% Improvement in JRA DOI at Month 6
Tidsramme: Baseline and month 6
|
Response was defined using the JRA definition of improvement (JRA DOI) as a ≥ 70% improvement from baseline in at least three of the six JRA Core Set Criteria and ≥ 30% worsening in not more than one of the six assessments. The JRA Core Set Criteria consist of:
|
Baseline and month 6
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Autoimmune sygdomme
- Ledsygdomme
- Muskuloskeletale sygdomme
- Reumatiske sygdomme
- Bindevævssygdomme
- Gigt
- Gigt, reumatoid
- Arthritis, Juvenil
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Gastrointestinale midler
- Dermatologiske midler
- Reproduktive kontrolmidler
- Abortfremkaldende midler, ikke-steroide
- Aborterende midler
- Folinsyreantagonister
- Etanercept
- Methotrexat
Andre undersøgelses-id-numre
- 20021628
- 016.0028 (Anden identifikator: Immunex Corporation)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Juvenil reumatoid arthritis
-
Centocor, Inc.Afsluttet
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiAfsluttet
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases...AfsluttetRheumatoid arthritis | Juvenil reumatoid arthritisForenede Stater
-
University of Missouri-ColumbiaAfsluttetJuvenil reumatoid arthritisForenede Stater
-
DePuy OrthopaedicsAfsluttetSlidgigt | Rheumatoid arthritis | Posttraumatisk gigt | Juvenil arthritisForenede Stater
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases...AfsluttetJuvenil reumatoid arthritisForenede Stater
-
AmgenImmunex CorporationAfsluttetJuvenil reumatoid arthritis
-
Bristol-Myers SquibbAfsluttetJuvenil reumatoid arthritisForenede Stater, Portugal, Italien, Brasilien, Tyskland, Peru, Frankrig, Spanien, Mexico, Østrig, Schweiz
-
AbbottEisai Co., Ltd.AfsluttetJuvenil reumatoid arthritisJapan
-
National Eye Institute (NEI)AfsluttetUveitis | Arthritis, Juvenil ReumatoidForenede Stater
Kliniske forsøg med Etanercept
-
EMSTrukket tilbageRheumatoid arthritisBrasilien
-
Shanghai Celgen Bio-Pharmaceutical Co.,LtdUkendtPsoriasis | Plaque PsoriasisKina
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...AfsluttetAnkyloserende spondylitisKina
-
mAbxience Research S.L.Rekruttering
-
Sun Yat-sen UniversityAfsluttet
-
AmgenAfsluttetArthritis, Reumatoid; Gigt, psoriasisForenede Stater, Puerto Rico
-
Samsung Bioepis Co., Ltd.AfsluttetRheumatoid arthritisPolen, Det Forenede Kongerige
-
AmgenAfsluttet
-
Sun Pharmaceutical Industries LimitedTrukket tilbage